Company profile: Gesynta Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical R&D developing mPGES-1–inhibiting drug candidates to reduce inflammation and pain. Pipeline includes vipoglanstat (GS-248), a non-hormonal treatment for endometriosis in phase II, and GS-073 for chronic inflammatory pain entering phase I. Research originates from Karolinska Institutet; GS-073 from AstraZeneca.
Products and services
- GS-073: A Phase I-ready mPGES-1-targeting drug candidate for chronic inflammatory pain, originating from AstraZeneca, developed to reduce inflammation and pain through inhibition of the pro-inflammatory enzyme mPGES-1
- MPGES-1 Inhibitor Portfolio Development: A clinical-stage program developing a portfolio of compounds that inhibit the pro-inflammatory enzyme mPGES-1, originating from Karolinska Institutet research, aimed at reducing inflammation and pain
- Vipoglanstat (GS-248): A non-hormonal mPGES-1 inhibitor currently in phase II clinical trials for endometriosis, demonstrated in preclinical studies to reduce endometriotic lesions and pain by inhibiting the pro-inflammatory enzyme mPGES-1
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Gesynta Pharma
IMMCO Diagnostics
HQ: United States
Website
- Description: Provider of innovative medical devices, diagnostic laboratory testing expertise, and pioneering research for a comprehensive solution to autoimmune disease diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IMMCO Diagnostics company profile →
Repertoire
HQ: United States
Website
- Description: Provider of clinical-stage immune medicines, offering the DECODE platform to identify TCRs and disease-relevant epitopes across all human HLAs; off-the-shelf TCR bispecific therapeutics that engage T cells via tumor-specific epitopes and an anti-CD3 moiety; mRNA cancer vaccines delivered via lipid nanoparticles; and mRNA tolerizing vaccines to induce T-cell anergy and expand regulatory T cells for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Repertoire company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
Alumis
HQ: United States
Website
- Description: Provider of precision medicine solutions focused on the discovery, development, and treatment of autoimmune disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alumis company profile →
BioSenic
HQ: United States
Website
- Description: Provider of therapies addressing innate immunity, inflammation, and organ/function repair, including arsenic trioxide-based treatments for autoimmune diseases and chronic graft versus host disease (ArsciCor, an oral formulation with rapid gastrointestinal solubilization and optimal bioavailability), cell therapy products for major bone defects and maxillofacial applications, and a Phase III trial of oral arsenic trioxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioSenic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Gesynta Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Gesynta Pharma
2.2 - Growth funds investing in similar companies to Gesynta Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Gesynta Pharma
4.2 - Public trading comparable groups for Gesynta Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →